SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude prices climb on concerns that Middle East shipping and energy-infrastructure attacks could disrupt supply. Traders are split between betting the geopolitical risk premium persists and expecting it to unwind if shipping normalizes or diplomacy advances, while many warn elevated oil could add to inflation pressure and weigh on broader markets.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Concerns about CoreWeaves debt-heavy expansion and borrowing costs, amplified by HSBCs warning that financing risks and slower AI demand could pressure growth, dominate the discussion. Bears question whether its backlog can offset funding needs, while bulls point to AI-compute demand and see the selloff as a buying or short-squeeze opportunity.

USA Rare Earth, Inc. is a domestic supplier of rare earth magnets and heavy rare earth elements. It develops a vertically integrated domestic supply chain for rare earth element magnet production, with a facility in Stillwater and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

A prolonged, steep selloff has fueled criticism of USA Rare Earths new CEO and board, with investors complaining about limited communication and questioning execution, cash burn, and potential share dilution. Some traders see the decline as an opportunity, citing the companys strategic role in domestic rare-earth supply chains and government backing, while others remain bearish amid sector-wide weakness.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is drawing attention amid a steep selloff to new lows, with traders linking the pressure to weakening Trump approval and approaching midterms, as well as concerns about Truth Social and the companys limited operating business. Some view the pending TAE fusion deal as a diversification opportunity, but note that it has not yet transformed the company.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid a steep post-IPO selloff, with traders pointing to successive lockup expirations and insider selling as potential supply pressure, alongside a TD Cowen price-target cut and concerns about valuation, growth and customer concentration. Bulls argue the shares are oversold and cite the companys AI hardware and backlog, while bears expect more downside; the discussion is predominantly bearish.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

Barclays downgrade and warning about commercial execution risks, particularly delays in securing a definitive TVA agreement, are driving concern around NuScales steep selloff. Traders are split between those worried the company cannot turn its reactor technology into firm projects and buyers who see the cash position and long-term nuclear demand as reasons to hold or accumulate.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is under pressure after its Q3 earnings beat failed to overcome disappointment with a full-year profit outlook that was narrowed without raising its midpoint, alongside weaker U.S. deliveries and market share. Traders debate whether the new buyback and stronger cash-flow outlook offset the cautious guidance, with some calling the selloff excessive.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforces agreement to acquire customer-engagement platform Braze is the main catalyst, with the deal expected to expand Marketing Cloud and its AI capabilities. Traders are weighing the strategic fit against the sizable cash outlay, and some are reacting negatively to CRMs weakness around the announcement.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GEs quarterly earnings beat and raised 2026 outlook are drawing attention, but shares are falling as traders weigh higher costs, weaker free cash flow and a loss in its insurance business against strong aerospace demand. Some see the report as a solid result, while others question whether services growth and margins can justify expectations.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTX is drawing attention after a broad quarterly earnings beat, raised full-year guidance, and a record backlog, reflecting strong defense and commercial aerospace demand. Traders are largely upbeat about the results, though some question how much of the guidance increase reflects cost recoveries and point to the shares weak reaction despite the strong report.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

aTyr Pharma (ATYR) Projected to Post Earnings on Wednesday

aTyr Pharma (NASDAQ:ATYR) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at...

aTyr Pharma, Inc. (NASDAQ:ATYR) Given Average Recommendation of "Hold" by Brokerages

Shares of aTyr Pharma, Inc. (NASDAQ:ATYR - Get Free Report) have been assigned an average recommendation of "Hold" from the seven research firms that are covering the stock, Marketbeat Ratings...

aTyr Pharma, Inc. (NASDAQ:ATYR) Given Average Recommendation of "Hold" by Analysts

aTyr Pharma, Inc. (NASDAQ:ATYR - Get Free Report) has been given a consensus recommendation of "Hold" by the seven research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a hold recomm...

aTyr Pharma (NASDAQ:ATYR) Upgraded at Wall Street Zen

Wall Street Zen raised shares of aTyr Pharma from a "sell" rating to a "hold" rating in a research note on Sunday...

aTyr Pharma Spotlights Efzofitimod Phase 3 Learnings, Eyes Mid-April FDA Type C Meeting

aTyr Pharma (NASDAQ:ATYR) CEO Sanjay Shukla outlined the company's strategy to develop new therapies for inflammation and fibrosis based on tRNA synthetase biology during a presentation at the...

Q1 Earnings Estimate for aTyr Pharma Issued By HC Wainwright

aTyr Pharma, Inc. (NASDAQ:ATYR - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of aTyr Pharma in a research report issued on Friday, March 6th...

ATYR PHARMA INC Q4 Loss Drops

(RTTNews) - aTYR PHARMA INC (ATYR) reported Loss for fourth quarter of -$13.96 million...

aTyr Pharma (NASDAQ:ATYR) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

aTyr Pharma (NASDAQ:ATYR - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by...

aTyr Pharma (ATYR) Expected to Announce Quarterly Earnings on Thursday

aTyr Pharma (NASDAQ:ATYR) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 12. (View Earnings Report at...

aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Recommendation of "Hold" by Analysts

Shares of aTyr Pharma, Inc. (NASDAQ:ATYR - Get Free Report) have been assigned an average recommendation of "Hold" from the seven brokerages that are presently covering the company, MarketBeat.com...

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

Why Is aTyr Stock Falling Today?

Equity

Bearish Sentiment

Shares of aTyr Pharma, Inc. (ATYR) plummeted 82% in Monday’s pre-market after the company announced that its late-stage study of Efzofitimod in 268 patients with pulmonary sarcoidosis did not meet the primary goal of steroid dose reduction from baseline at week 48.However, clinical benefit for Efzofitimod was observed across multiple study parameters, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-topline-results-phase-3-efzo-fittm-study">said</a>. aTyr Pharma announced that it plans to engage with the U.S. Food and Drug Administration (FDA) to review the results and determine the path forward for Efzofitimod in the treatment of pulmonary sarcoidosis.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ATYR">ATYR stock</a> jumped from 'bullish' to 'extremely bullish' territory over the past 24 hours, while message volume stayed at 'extremely high' levels.&nbsp;Pulmonary sarcoidosis is an inflammatory disease characterized by the formation of clumps of inflammatory cells in one or more organs of the body. It can cause permanent loss of lung function in some patients. According to the company, about 200,000 Americans live with the condition. A total of 268 patients with pulmonary sarcoidosis were enrolled in the late-stage study.The company stated that the change from baseline in mean daily oral corticosteroid dose was reduced to an average of 2.79 mg for 5.0 mg/kg Efzofitimod, compared to 3.52 mg for the placebo in the trial. Complete steroid withdrawal was achieved for 52.6% of patients treated with 5.0 mg/kg efzofitimod vs 40.2% on placebo, it added.The study, however, showed clinical improvement in the King’s Sarcoidosis Questionnaire (KSQ)-Lung score at week 48 for 5.0 mg/kg Efzofitimod compared to placebo. The questionnaire is designed to assess the impact of sarcoidosis on various aspects of life. Further, lung function was maintained at week 48, the company said. aTyr believes these findings indicate drug activity for Efzofitimod.ATYR stock is down 70% this year and approximately 43% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/trump-fed-rate-cut-this-week-too-late-powell-bigger-than-he-had-in-mind/chwwONNRdUh">Trump Says ‘Too Late’ Powell Must Cut Rates Now, And ‘Bigger Than He Had In Mind’ Ahead Of Fed Meeting This Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The company announced that it plans to engage with the U.S. Food and Drug Administration (FDA) to review the results and determine the path forward for Efzofitimod in the treatment of pulmonary sarcoidosis.

aTyr Pharma, Inc

iShares Russell 2000 BuyWrite ETF

Vanguard Russell 2000 Growth ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$0.1717
Prev Close	$0.174
Open	$0.1799
Dividend Yield	0.00%
50-Day Moving Average	$0.3988
Beta	1.06
Avg. Volume	7.81M
PE Ratio	-0.28

52-Week High	$1.11
52-Week Low	$0.165
Market Capitalization	$16.84M
EPS (Annual)	-$0.7971
Price to Book	0.35
Revenue Per Employee	$3,275.86

Feed

News

Sentiment

Earnings

Fundamentals

Info

ATYR Fundamentals